Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens

Introduction Dolutegravir/lamivudine (DTG/3TC) is a 2-drug regimen for HIV-1 treatment with long-term efficacy and good tolerability comparable to 3- or 4-drug regimens. This study evaluated DTG/3TC cost versus other standard single-tablet regimens during its first year of approval. Methods This ret...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Infectious diseases and therapy Ročník 12; číslo 8; s. 2117 - 2133
Hlavní autoři:	Priest, Julie, Germain, Guillaume, Laliberté, François, Duh, Mei Sheng, Mahendran, Malena, Fakih, Iman, Oglesby, Alan
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Cheshire Springer Healthcare 01.08.2023 Springer Springer Nature B.V Adis, Springer Healthcare
Témata:	2-drug regimen Analysis Antiretroviral drugs Costs Darunavir Dolutegravir/lamivudine Drug approval Drugstores Economic aspects Health care Health care expenditures Healthcare costs HIV (Viruses) HIV-1 Infectious Diseases Integrase strand transfer inhibitor Internal Medicine Medical care, Cost of Medicine Medicine & Public Health Original Research Pharmacy Single-tablet regimen HIV-1 Integrase strand transfer inhibitor Healthcare costs Dolutegravir/lamivudine Single-tablet regimen 2-drug regimen
ISSN:	2193-8229, 2193-6382
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!